Cargando…

TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases

Mutations in tumor suppressor TP53 have been inconsistently linked to breast cancer risk factors and survival. Immunohistochemistry (IHC) staining, a primary clinical means of TP53 mutation determination, only detects mutations that facilitate protein accumulation (e.g., missense mutations). RNA-bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Lindsay A., Butler, Ebonee N., Sun, Xuezheng, Allott, Emma H., Cohen, Stephanie M., Fuller, Ashley M., Hoadley, Katherine A., Perou, Charles M., Geradts, Joseph, Olshan, Andrew F., Troester, Melissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018637/ https://www.ncbi.nlm.nih.gov/pubmed/29951581 http://dx.doi.org/10.1038/s41523-018-0067-5

Ejemplares similares

TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study
por: Hurson, Amber N., et al.
Publicado: (2022)

Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases
por: Hurson, Amber N., et al.
Publicado: (2022)

Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype
por: Couture, Heather D., et al.
Publicado: (2018)

Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features
por: Benefield, Halei C, et al.
Publicado: (2020)

Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study
por: Parada, Humberto, et al.
Publicado: (2017)

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications
por: Allott, Emma H., et al.
Publicado: (2019)

Gene expression patterns associated with p53 status in breast cancer
por: Troester, Melissa A, et al.
Publicado: (2006)

Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification
por: Allott, Emma H., et al.
Publicado: (2016)

Prediction of Toxicant-Specific Gene Expression Signatures after Chemotherapeutic Treatment of Breast Cell Lines
por: Troester, Melissa A., et al.
Publicado: (2004)

Hepatocyte growth factor pathway expression in breast cancer by race and subtype
por: Jones, Gieira S., et al.
Publicado: (2021)

Impact of stromal microenvironment on metabolic phenotypes in breast cancer: evidence for stroma-influenced Warburg effect
por: Brauer, Heather Ann, et al.
Publicado: (2012)

Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study
por: Williams, Lindsay A., et al.
Publicado: (2019)

Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study
por: Shi, Yifeng, et al.
Publicado: (2023)

Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy–driven Metabolic Reprogramming
por: McClure, Marni B., et al.
Publicado: (2023)

A framework for transcriptome-wide association studies in breast cancer in diverse study populations
por: Bhattacharya, Arjun, et al.
Publicado: (2020)

Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer
por: Patel, Achal, et al.
Publicado: (2022)

Frequency of breast cancer subtypes among African American women in the AMBER consortium
por: Allott, Emma H., et al.
Publicado: (2018)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study
por: Walsh, Tom, et al.
Publicado: (2021)

Breast exam use during the protracted COVID-19 pandemic, by age, race, and geography
por: Butler, Eboneé N, et al.
Publicado: (2023)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment
por: Butler, Eboneé N., et al.
Publicado: (2020)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Integrated RNA and DNA sequencing improves mutation detection in low purity tumors
por: Wilkerson, Matthew D., et al.
Publicado: (2014)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Identification of mRNA isoform switching in breast cancer
por: Zhao, Wei, et al.
Publicado: (2016)

EGFR associated expression profiles vary with breast tumor subtype
por: Hoadley, Katherine A, et al.
Publicado: (2007)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer
por: Thorner, Aaron R., et al.
Publicado: (2010)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r4tbqtgum13vrq19vpfp4ja69e